Umang Patel, MD
Radiation Oncology · The Woodlands, TXNPI 1700176369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $691 and has fallen 71.2% since, to $199 in 2025.
Across 152 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$441
- Myriad Genetic Laboratories, Inc.$408
- Bayer$245
- Tactile Systems Technology Inc$216
- Merck$165
- Blue Earth Diagnostics$156
- plus $1K from 37 others
Across 2 payments — averaging $22,871 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$46K
What the payments were for
- Food & beverage$2,94197%
- Education$783%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolaris$137
How this compares
$3,019 in reported general payments places this provider in the 80th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 22 | $986 |
| Tamsulosin Hcl | 93 | $860 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 61 | $533 |
| Dexamethasone | 11 | $366 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $248 |
| Lorazepam | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in The Woodlands
- Jason BerilgenThe Woodlands$11K
- Nena MirkovicThe Woodlands$7K
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.